Repurposing cysteamine as a rapdily deployable intervention for COVID-19

点击翻译按钮获取中文摘要

Nylexa is a repurposed therapy, already in advanced development for chest infections in CF patients, that can be rapidly deployed as a treatment for COVID-19\.Nylexa is unique and potentially game-changing, because it has multiple targets; the nSARS-CoV-2 virus, the immune response to the infection and also the complications of intractable bacterial infections secondary to SARS-CoV-2 that result in as many as 20% of COVID-19 deaths currently and more than 50% early in the outbreak (in Hubei Province, China).Nylexa is an antimicrobial-immunomodulator with the potential to alter the trajectory of this disease. To save lives and aid better recovery of those infected with less permanent lung damage. It can be rapidly and safely tested (as an intravenously infused drug) in hospitalised COVID-19 patients in the UK and thereafter, worldwide.Nylexa isn't just great science, it is a truly viable solution to COVID-19: Cost effective, readily available and scalable, such that it can be deployed on the global scale required post successful, expedited clinical testing and approvals. NovaBiotics is perfectly positioned to deliver this outcome as a leading biotechnology company developing first-in-class anti-infective and respiratory disease therapies. The business has a track record of developing novel drug candidates from invention to late stage clinical development and commercialisation thereafter through partnerships with pharmaceutical entities with manufacturing and sales-distribution infrastructure.Nylexa could not only be transformational on outcomes of the COVID-19 pandemic, but for NovaBiotics. Nylexa could potentially become NovaBiotics' first approved drug and could pivot the business to profitability, allowing company growth and re-investment in research and development to advance the company's other, potentially life-saving antimicrobial medicines for bacterial and fungal disease, which could have even greater benefit to society and the economy than Nylexa.